If inducer is discontinued, consider oliceridine dosage reduction and monitor for signs of respiratory melancholy.
pentobarbital will reduce the extent or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will lessen the extent or result of carvedilol by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.
Monoamine oxidase inhibitors (MAOI) could inhibit barbiturate metabolism and prolong barbiturate effects; monitor carefully
pentobarbital will lessen the extent or influence of midostaurin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Solid CYP3A4 inducers may well minimize midostaurin concentrations causing diminished efficacy.
Estradiol valerate/dienogest should not be applied for at least 28 times after discontinuation on the inducer resulting from possibility of lowered contraceptive efficacy.
pentobarbital will decrease the level or outcome of bosentan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Mysterious.
pentobarbital here will reduce the level or result of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.
pentobarbital will minimize the level or result of propafenone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
pentobarbital will decrease the extent or influence of atazanavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital will lower the level or result of larotrectinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
To reduce the opportunity of overdosage or the development of dependence, limit the prescribing and dispensing of sedative-hypnotic barbiturates, to the quantity required for your interval right until the next appointment
pentobarbital will lessen the extent or influence of rolapitant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Very long-time period coadministration of powerful CYP3A4 inducers with rolapitant could drastically lower rolapitant efficacy.